Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takeshi Usui is active.

Publication


Featured researches published by Takeshi Usui.


Circulation | 1994

Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system.

Osamu Nakagawa; Issei Tanaka; Takeshi Usui; Masaki Harada; Yutaka Sasaki; Hiroshi Itoh; Takaaki Yoshimasa; Tsunehisa Namba; Shuh Narumiya; Kazuwa Nakao

BACKGROUND Prostacyclin elicits a potent vasodilation and inhibition of platelet aggregation through binding to its membrane receptor. The impairment of prostacyclin receptor activity is implicated in various human cardiovascular diseases. In the present study, we succeeded in the isolation and characterization of human prostacyclin receptor cDNA and elucidated its gene expression in human tissues. METHODS AND RESULTS We isolated a cDNA clone encoding the human prostacyclin receptor from a human lung cDNA library. The isolated cDNA clone encodes a 386-amino acid protein with seven putative transmembrane domains, which belongs to the G protein-coupled receptor superfamily. [3H]iloprost, a prostacyclin receptor agonist, specifically bound to the receptor transiently expressed in COS-7 cells. The binding was inhibited in the rank order of iloprost = cicaprost, another prostacyclin receptor agonist, > prostaglandin E1 (PGE1) >> PGE2, PGF2 alpha, PGD2, STA2. In addition, iloprost dose-dependently stimulated cAMP generation in these COS-7 cells. These results are consistent with the characteristics of the human prostacyclin receptor. Northern blotting analysis on human tissues revealed that prostacyclin receptor mRNA is abundantly expressed in the aorta, lung, atrium, ventricle, and kidney. CONCLUSIONS We cloned human prostacyclin receptor cDNA and elucidated its abundant gene expression in the human cardiovascular system. The present study will lead to better understanding of the significance of prostacyclin in humans and further facilitate the clinical application of prostacyclin.


Brain Research | 1997

Tumor necrosis factor receptors in the pituitary cells

Hiromasa Kobayashi; Junichi Fukata; Norihiko Murakami; Takeshi Usui; Osamu Ebisui; Seiji Muro; Ikuko Hanaoka; Kinji Inoue; Hiroo Imura; Kazuma Nakao

To clarify the site and mode of action of tumor necrosis factor (TNF) in the pituitary, we studied the effects, binding sites of TNF and its receptor mRNA in the two types of mouse pituitary-derived cell lines, AtT-20, ACTH-producing cells and TtT/GF, folliculo-stellate (FS)-like cells. First, we examined the expression of TNF receptor mRNA in these cells. Using Northern blot analyses with radiolabeled cDNA to murine TNF receptor p60 and p80 mRNAs as probes, we identified both types of mRNA in the poly(A)-containing RNA prepared from AtT-20 cells and p60 TNF receptor mRNA from TtT/GF. The identified mRNA were compatible in size with those detected in the immune-competent cells. Next, we studied the TNF-binding sites on these cells. Scatchard plot analysis of the significant binding of [125I]TNF revealed a single type of binding site with a Kd (dissociation constant) of 210 pM and 131 binding sites/cell on AtT-20. Similarly on TtT/GF, [125I]TNF showed 353 binding sites/cell with a Kd of 900 pM. [125I]TNF binding on both types of cells competed with TNF and lymphotoxin (TNF beta) in an equimolar fashion. Third, TNF stimulates ACTH synthesis in AtT-20 cells, while TNF increases immunoreactive interleukin (IL)-6 release from TtT/GF cells. These findings demonstrate that AtT-20 and TtT/GF cells are equipped with fully functional TNF receptor system, and suggest that ligand of the receptor, TNF alpha and/or TNF beta, can modulate ACTH synthesis and release as a direct hormonal effector on corticotrophs or indirect modulator through another paracrine mediator, such as IL-6 from FS cells.


Clinical Endocrinology | 2013

Effects of natural S‐equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status

Takeshi Usui; Mayu Tochiya; Yousuke Sasaki; Kazuya Muranaka; Hajime Yamakage; Akihiro Himeno; Akira Shimatsu; Asami Inaguma; Tomomi Ueno; Shigeto Uchiyama; Noriko Satoh-Asahara

Epidemiologic studies indicate that soy intake has an important role in the prevention of age‐related health problems. Daidzein, the principal isoflavone contained in soy, is converted to S‐equol by the intestinal bacteria. Not all individuals, however, can produce S‐equol, which is considered the most biologically active metabolite. We studied the effects of a natural S‐equol supplement on metabolic parameters associated with overweight or obesity and metabolic syndrome.


The Journal of Clinical Endocrinology and Metabolism | 2012

Confirmatory Testing in Primary Aldosteronism

Kazutaka Nanba; Tamiko Tamanaha; Kanako Nakao; Sachiko-Tsukamoto Kawashima; Takeshi Usui; Tetsuya Tagami; Hiroshi G. Okuno; Akira Shimatsu; Tomoko Suzuki; Mitsuhide Naruse

CONTEXT Although confirmatory testing to verify aldosterone excess is a key step in the diagnosis of primary aldosteronism (PA), there is no consensus as to whether it is always needed and which of the tests need to be performed. OBJECTIVE The objective of this study was to investigate the diagnostic significance of confirmatory tests in PA. DESIGN AND PATIENTS In group A, 120 hypertensive patients who had positive case detection using the aldosterone to renin ratio (ARR) were subjected to at least one confirmatory test: the captopril challenge test (CCT), furosemide upright test (FUT), or saline infusion test (SIT). Among group A, 57 patients underwent all three confirmatory tests (group B), and 57 patients were differentiated as having either unilateral or bilateral PA based upon adrenal venous sampling, adrenal scintigraphy, and/or adrenal surgery (group C). RESULTS The percentages of patients with positive CCT and FUT were 86 and 87% in group A, 88 and 88% in group B, and 96 and 94% in group C, respectively. The percentage of patients with positive SIT results was lower than that with other tests (P < 0.01). The percentage of patients with positive results for the three tests was higher in patients with baseline ARR of at least 1000 or plasma aldosterone concentration (PAC) of at least 250 pg/ml than in those with lower ARR or PAC in all three groups. CONCLUSIONS Most patients with positive case detection also had positive results on the CCT and FUT, especially when ARR was at least 1000 or PAC was at least 250 pg/ml under renin suppresion. Confirmatory testing for PA may not be needed in all patients with positive case detection.


Clinical Endocrinology | 2009

P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease.

Sachiko-Tsukamoto Kawashima; Takeshi Usui; Toshiaki Sano; Hitomi Iogawa; Hanae Hagiwara; Tamiko Tamanaha; Tetsuya Tagami; Mitsuhide Naruse; Masato Hojo; June A. Takahashi; Akira Shimatsu

© 2009 The Authors Journal compilation


Journal of Molecular Medicine | 1996

Gene expression of the human prostaglandin E receptor EP4 subtype: differential regulation in monocytoid and lymphoid lineage cells by phorbol ester

Kiyoshi Mori; Issei Tanaka; Masato Kotani; F. Miyaoka; Takehiro Sando; Seiji Muro; Yutaka Sasaki; Osamu Nakagawa; Yoshihiro Ogawa; Takeshi Usui; Shoichi Ozaki; Atsushi Ichikawa; Shuh Narumiya; Kazuwa Nakao

We isolated a cDNA clone encoding the human prostaglandin (PG) E receptor EP4 subtype and examined the gene expression in human blood cells. Northern blot analysis revealed that the EP4 gene is expressed at a high level in peripheral blood mononuclear cells, and at lower levels in cultured human blood cell lines, THP-1 and U937 (monocytoid cell lines), MOLT-4 and Jurkat (T-cell lines), and Raji (B-cell line). To examine regulation of the EP4 gene expression in the immune system, we studied the effects of phorbol 12-myristate 13-acetate (PMA) on these cell lines. Gene expression was upregulated in THP-1, U937, and Raji cells by PMA, and was downregulated in MOLT-4 and Jurkat cells. In THP-1 cells the effects of PMA were further analyzed, and the upregulation of the EP4 gene was shown to be followed by an increase in PGE2 binding sites and in PGE2-induced cAMP accumulation. In the striking contrast, other PGE receptor subtypes (EP1, EP2 and EP3) and other prostanoid receptors (IP and DP) were shown not to be upregulated by PMA. Therefore, this is the first demonstration of a highly specific upregulation of the EP4 subtype in THP-1 cells treated with PMA, suggesting the importance of the EP4 subtype in the immune system. In the present study we also clarified that EP4 gene expression is regulated differently among human monocytoid and lymphoid lineage cells, thus leading to the better understanding of the regulatory mechanisms for the human EP4 gene expression in the immune system.


Neuroscience Letters | 1986

Effects of food deprivation and high fat diet on opioid receptor binding in rat brain.

Satoru Tsujii; Yoshikatsu Nakai; Junichi Fukata; Toshikiyo Koh; Hideo Takahashi; Takeshi Usui; Hiroo Imura

The effect of food deprivation for 72 h or a high fat diet on [3H]naloxone binding in the discrete brain regions of male lean Zucker rats was studied. In the midbrain, both treatments increased Bmax for the high-affinity site with no change in Kd. In the cortex, the high fat diet increased Bmax for the high-affinity site. These results suggest that dietary manipulations could produce significant changes in the endogenous opioid system.


Brain Research | 1986

Effect of food deprivation on opioid receptor binding in the brain of lean and fatty Zucker rats.

Satoru Tsujii; Yoshikatsu Nakai; Toshikiyo Koh; Hideo Takahashi; Takeshi Usui; Hitoshi Ikeda; Takao Matsuo; Hiroo Imura

The effect of food deprivation on opioid receptor binding was studied in 6 brain regions of lean and fatty Zucker rats; using [3H]dynorphin A. There was no significant difference between lean and fatty rats fed ad libitum in binding parameters for any regions studied. Food deprivation increased Bmax and/or Kd for cortex, midbrain and striatum of lean rats, and the former two regions of fatty rats. These results suggest that food deprivation may influence opioid receptor binding in lean and fatty Zucker rats.


Physiology & Behavior | 1988

Monoamine metabolism and its responses to food deprivation in the brain of Zucker rats

Satoru Tsujii; Yoshikatsu Nakai; Junichi Fukata; Shigeo Nakaishi; Hideo Takahashi; Takeshi Usui; Hiroo Imura; Hitoshi Ikeda; Takao Matsuo

Monoamines and their metabolites levels were simultaneously measured by high-performance liquid chromatography in brain regions of lean and fatty Zucker rats when fed ad lib and deprived of food for 72 hr to evaluate each monoamine metabolism. Metabolite/monoamine ratios were shown for brevity to represent its metabolism. 3-Methoxy-4-hydroxyphenylethyleneglycol/noradrenaline ratios were not affected by the phenotype factor but increased in the cortex of fatty rats and reduced in the midbrain of both phenotypes after fasting; the interaction between phenotype and feeding factors was observed in the cortex and hippocampus. 3,4-Dihydroxyphenylacetic acid/dopamine ratios were increased in the cortex of deprived fatty rats and in the medulla-pons of ad lib-fed fatties compared with lean counterparts and also increased in the striatum of lean rats after food deprivation; the interaction was observed in the cortex, midbrain and medulla-pons. Homovanillic acid/dopamine ratios were decreased in the striatum of deprived fatty rats and in the midbrain and medulla-pons of fatty rats whether deprived or not, but the ratios were not significantly changed by fasting; the interaction was observed in the striatum. 5-Hydroxyindoleacetic acid/5-hydroxytryptamine ratios were reduced in the cortex, striatum and medulla-pons of fatty rats in both feeding states and in the midbrain of deprived fatties, and after food deprivation increased in the cortex and midbrain of lean rats and in the hippocampus of both phenotypes; the interaction was observed in the midbrain.(ABSTRACT TRUNCATED AT 250 WORDS)


Pituitary | 2011

Successful treatment of Cushing’s disease caused by ectopic intracavernous microadenoma

Mitsuteru Koizumi; Takeshi Usui; Shozo Yamada; Ichiro Fujisawa; Tsunehisa Tsuru; Kazutaka Nanba; Hanae Hagiwara; Takashi Kimura; Tamiko Tamanaha; Tetsuya Tagami; Mitsuhide Naruse; Akira Shimatsu

Adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas are sometimes difficult to visualize, even with high-quality magnetic resonance imaging, due to their small size and variable location. Sampling the cavernous or inferior petrosal sinus is helpful for confirming the central origin of a tumor, but ectopic corticotroph adenomas in the paraseller region also typically exhibit a high central/peripheral plasma ACTH ratio. We experienced an extremely rare case of Cushing’s disease caused by an ACTH-secreting microadenoma located entirely inside the left cavernous sinus attached to the medial wall (ectopic pituitary adenoma) that was not visible by preoperative MRI. In this case, the microadenoma was completely removed and an endocrinologic cure was achieved. This case reveals that in addition to meticulous sectioning of the pituitary gland, bilateral periglandular inspection with visualization of the medial wall of the cavernous sinus and of the diaphragm should always be performed to detect ectopic parasellar microadenomas when no adenoma is visible by preoperative MRI.

Collaboration


Dive into the Takeshi Usui's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge